Robot arm takes on colon polyps: new study tests less invasive removal
NCT ID NCT06133387
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study is testing a robotic device that doctors use through the anus to remove benign growths (polyps, adenomas) from the rectum and sigmoid colon. The goal is to see if the device can remove the entire growth in one piece safely, without causing bleeding or a hole in the bowel. About 56 adults with such growths will be treated and followed for 30 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Endoluminal Surgical (ELS) System (robotic device)
- What this could lead to
- If successful, this robotic device could offer a less invasive way to remove colorectal polyps and adenomas, reducing the need for traditional surgery.
- What could go wrong
- This is an early-stage study with only 56 participants, so results may not apply widely. Risks include bleeding or perforation during the procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Preoperative Inclusion Criteria: 1. Subject is ≥22 years at the time of consent. 2. Subject has a BMI ≤ 50 kg/m2. 3. Subject has an ASA score of ≤ 3. 4. Subject has benign lesion(s) of the rectum or sigmoid colon, such as adenoma (with low- or high-grade dysplasia), neuroendocrine tumor, or other type of polyp as assessed by the most recent colonoscopy/flexible sigmoidoscopy. 5. Subject has lesion ≤ 7 cm in size (dimension of greatest extent) and ≤ 75% of the colorectal circumference as assessed by the most recent colonoscopy/flexible sigmoidoscopy. 6. Subject is eligible for standard endoscopic submucosal dissection. 7. Subject agrees to participate in the study by giving signed informed consent. Preoperative Exclusion Criteria: 1. Subject anatomy is unsuitable for endoscopic visualization or endoluminal surgery. 2. Subject has active left-sided inflammatory bowel disease. 3. Subject has an untreated active infection at the time of the procedure. 4. Subject is considered part of a vulnerable population (e.g., prisoners, mentally disabled). 5. Subject has a severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions (e.g., cancer). 6. Subject is breastfeeding or pregnant or intends to become pregnant during the study. 7. Subject is currently enrolled in or discontinued within the last 30 days from a clinical trial of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. 8. Subject with EF ≤ 45, high cardiac or high pulmonary risk (these subjects require clearance from a cardiologist and pulmonologist, as applicable). 9. Subject on preoperative blood thinners, such as coumadin or heparin, that cannot be weaned prior to surgery. 10. Subject is moderately or severely immunocompromised. 11. In the opinion of the Investigator, the subject is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. Intraoperative Exclusion Criteria (assessed with third-party endoscope): 1. Inadequate bowel prep. 2. Complex anatomical findings not feasible for an endoluminal approach. 3. Anatomical narrowing distal to the lesion site. 4. Lesion not located in the rectum or sigmoid colon. 5. Lesion size \>7 cm (dimension of greatest extent) or occupies \>75% of the colorectal circumference. 6. Lesion demonstrates characteristics indicative of invasive carcinoma, such as failure to lift upon submucosal injection, or any other features that raise the Investigator's suspicion of cancer. Intraoperative Exclusion Criteria (assessed with study device): 7. In the opinion of the Investigator, the subject and/or subject anatomy is not suitable for study device use for any reason. 8. Lesion location not accessible by the study device.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Benign colorectal lesion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth
Orlando, Florida, 32803, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
HCA Healthcare
Houston, Texas, 77004, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI measures bowel cleanliness to boost polyp detection
- AI may catch precancerous polyps from simple blood tests
- AI eyes colon polyps: can it spot the dangerous ones?
- Can armored CAR t cells take down Hard-to-Treat neuroendocrine cancers?
- A simple blood draw could spot tumor relapse before scans do
- Can beans beat obesity and colon cancer?